Literature DB >> 15350507

Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry.

Karina Godoy-Ramirez1, Kristina Franck, Shahnaz Mahdavifar, Lena Andersson, Hans Gaines.   

Abstract

The assessment of cytokine production is an important component of studies of cell-mediated immune responses (CMI) to immunological challenges. In this study, we present a method to enhance the detection of cytokine-producing cells by allowing antigen-specific cells to expand in long-term culture. We investigated the influence of the degree of dilution of whole blood and the duration of the incubation period on whole blood as well as peripheral blood mononuclear cells (PBMCs), cultured in the absence or presence of mitogens, superantigens or specific antigens, for intracellular cytokine production (IFNgamma, TNFalpha, IL-2, IL-4, IL-10 and IL-13) by CD4+ and CD8+ T lymphocytes using four-colour flow cytometry. Whole blood was diluted 1/1, 1/2, 1/5 and 1/10, and cultured for 6, 24, 48, 72 and 120 h in the presence of antibodies against the co-stimulatory molecules CD28 and CD49d, and, during the last 4 h of culture, in the presence of brefeldin A. Optimum conditions for detection of a high number of IFNgamma-positive cells were observed after 72 h of culture in blood diluted 1/10. Median frequencies of IFNgamma+ cells obtained after activation by PMA-ionomycin, PHA or SEA-B were 29.3%, 20.0% and 6.8% for CD4+ cells, and 67.8%, 20.6% and 6.8% for CD8+ cells. In blood samples diluted 1/5 or 1/10, and cultured in the presence of cytomegalovirus (CMV) or varicella-zoster virus (VZV), mean peak levels of 2.8% and 1.4% IFNgamma+CD4+ cells were recorded at 120 h. The levels of cells producing cytokines other than IFNgamma were generally much lower and, in the case of IL-4 and IL-13, difficult to distinguish from background levels recorded in cultures with medium only. Kinetic studies of cytokine production by PBMCs showed a pattern similar to that of whole blood with peak levels of IFNgamma-producing cells recorded at 72 h. The increased levels of IFNgamma production after culture for 72 h were due to an expansion of the numbers of cytokine-producing cells responsive to a specific stimulus. Antigen-specific cells are usually present only at low levels in peripheral blood and may not be detected following simple activation for a few hours. To reach a level of detection in such cases, culture of diluted blood for several days is recommended.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350507     DOI: 10.1016/j.jim.2004.04.028

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  21 in total

1.  A novel dendritic cell-based direct ex vivo assay for detection and enumeration of circulating antigen-specific human T cells.

Authors:  Roberto Carrio; Ge Zhang; Donald R Drake; Brian C Schanen
Journal:  Cytotechnology       Date:  2018-05-07       Impact factor: 2.058

2.  Quantitative and functional differences between peripheral blood myeloid dendritic cells from patients with pleural and parenchymal lung tuberculosis.

Authors:  Marc Mendelson; Willem A Hanekom; Siyabulela Ntutela; Monica Vogt; Lafras Steyn; Gary Maartens; Gilla Kaplan
Journal:  Clin Vaccine Immunol       Date:  2006-09-27

3.  Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.

Authors:  David Guillén; Federico Cofán; Emilio Ros; Olga Millán; Montse Cofán; Mercè Brunet
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

4.  Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification.

Authors:  Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

5.  Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation.

Authors:  John M Davis; Cynthia S Crowson; Keith L Knutson; Sara J Achenbach; Michael A Strausbauch; Terry M Therneau; Eric L Matteson; Sherine E Gabriel; Peter J Wettstein
Journal:  Clin Immunol       Date:  2020-01-08       Impact factor: 3.969

6.  Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis.

Authors:  Megan L Krause; John M Davis; Keith L Knutson; Michael A Strausbauch; Michael A Strausbach; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel
Journal:  Clin Immunol       Date:  2011-05-30       Impact factor: 3.969

7.  Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation.

Authors:  Carmen Martínez; Olga Millán; Montserrat Rovira; Francesc Fernández-Avilés; Anna López; María Suárez-Lledó; Enric Carreras; Álvaro Urbano-Ispízua; Mercè Brunet
Journal:  Int J Hematol       Date:  2016-11-23       Impact factor: 2.490

8.  CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses.

Authors:  Kristin Scheible; Gang Zhang; Jane Baer; Mitra Azadniv; Kris Lambert; Gloria Pryhuber; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

9.  Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model.

Authors:  M Mancini-Bourgine; G Guillen; M L Michel; J C Aguilar
Journal:  Euroasian J Hepatogastroenterol       Date:  2014-01-22

Review 10.  Cytokines and other immunological biomarkers in children's environmental health studies.

Authors:  Paurene Duramad; Ira B Tager; Nina T Holland
Journal:  Toxicol Lett       Date:  2007-05-25       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.